ArticleFrontiers in microbiology2015
Characterization and evaluation of antimicrobial and cytotoxic effects of Streptomyces sp. HUST012 isolated from medicinal plant Dracaena cochinchinensis Lour.
Article in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Isolation and characterization of an endophytic Streptomyces sp. YBRX0 from Croton tonkinensis and assessment of its bioactive potential.Journal, genetic engineering & biotechnology · 2026Article
- Review
- Screening, Identification, and Fermentation Optimization of the Antagonistic Actinomycete Strain TCS21-117 AgainstMicroorganisms · 2025Article
- Metabolites limiting predator growth wane with prey biodiversity.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Draft genome sequence ofMicrobiology resource announcements · 2023Article
- Antagonistic Potentiality of Actinomycete-Derived Extract with Anti-Biofilm, Antioxidant, and Cytotoxic Capabilities as a Natural Combating Strategy for Multidrug-Resistant ESKAPE Pathogens.Journal of microbiology and biotechnology · 2023Article
- Article
- Isolation and Identification of Bioactive Compounds fromAntibiotics (Basel, Switzerland) · 2022Article
- Genome-Guided Investigation Provides New Insights into Secondary Metabolites ofPolish journal of microbiology · 2022Article
- Exploring in vitro anti-proliferative and anti-inflammatory activities of Prasachandaeng remedy, and its bioactive compounds.BMC complementary medicine and therapies · 2022Article
- Biocontrol of strawberry gray mold caused byFrontiers in microbiology · 2022Article
- Evaluation of the anticarcinogenic potential of the endophyte, Streptomyces sp. LRE541 isolated from Lilium davidii var. unicolor (Hoog) Cotton.Microbial cell factories · 2021Article
- Potential secondary metabolite from Indonesian Actinobacteria (InaCC A758) againstIranian journal of basic medical sciences · 2021Article
- Biodiversity of Secondary Metabolites Compounds Isolated from Phylum Actinobacteria and Its Therapeutic Applications.Molecules (Basel, Switzerland) · 2021Review
- Article
- Isolation, characterization, anti-MRSA evaluation, and in-silico multi-target anti-microbial validations of actinomycin XScientific reports · 2021Article
- In Vivo Studies of Inoculated Plants and In Vitro Studies Utilizing Methanolic Extracts of EndophyticInternational journal of molecular sciences · 2020Article
- Review
- Study of in vitro interaction between Fusarium verticillioides and Streptomyces sp. using metabolomics.Folia microbiologica · 2020Article
- Critical Assessment ofInternational journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A highly potent secondary metabolite producing endophytic strain, Streptomyces sp. HUST012 was isolated from the stems of the medicinal plant Dracaena cochinchinensis Lour. Strain HUST012 showed antimicrobial and antitumor activities which were significantly much higher than those of dragon's blood extracted from D. cochinchinensis Lour. On further analysis, the strain was found to produce two metabolites, SPE-B11.8 (elucidated to be a novel metabolite (Z)-tridec-7-ene-1,2,13-tricarboxylic acid) and SPE-B5.4 (elucidated as Actinomycin-D). The Minimum Inhibitory Concentration values of SPE-B11.8 against a set of test bacterial organisms (Methicillin-resistant Staphylococcus epidermis ATCC 35984, Methicillin-resistant Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, and Klebsiella pneumoniae ATCC 13883) ranged between 15.63 and 62.5 μg/ml while that for SPE-B5.4 ranged between 0.04 and 2.24 μg/ml. The compound SPE-B11.8 showed cytotoxic effect at 41.63 and 29.54 μg/ml IC 50-values against Hep G2 and MCF-7, respectively, while the compound SPE-B5.4 exhibited stronger activities against them at 0.23 and 0.18 μg/ml IC 50-values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.